Deficiency of iduronate-2-sulphatase
(IDS) results in the X linked recessive lysosomal storage disorder Hunter syndrome. Determination of carrier status in families affected by this disorder has been performed using a variety of enzymatic tests. None of these tests has proved to be 100% effective at identifying carriers. The aim of this study was to perform carrier testing in a family affected by the disorder, where testing was complicated by the fact that no surviving affected subjects were available for study. Direct dye primer sequencing of PCR products was used to identify mixed bases in an obligate carrier. Two mixed bases were observed within exon VIII. The first base change (T-*A) at nucleotide position 1150 results in a missense mutation (H342Q), while the second base change (G-*T) at nucleotide position 1151 results in a nonsense mutation (G343X). Four additional female family members were screened for the same mutation. Using this approach it is possible to provide unambiguous information about a subject's carrier status and, unlike biochemical testing, this approach will be equally effective when applied to families with the PCR products were gel purified using a QIAquick Gel Extraction Kit (Qiagen Inc, Santa Clarita, CA) and then sequenced directly using universal and reverse BODIPY dye primers as previously described.'6 Dye terminator universal and reverse reads were performed on cloned DNA using reagent kits provided by PE Applied Biosystems (Foster City, CA). Reactions were performed on PEC 9600 thermocyclers and electrophoresed on ABI 373 or 377 DNA sequencers. Sequence analysis was carried out using Sequencher Version 3.0 (Gene Codes Corporation).
Results
Approximately 20% of cases of Hunter syndrome are the result of major structural rearrangements (deletions or rearrangements) within the IDS gene.4 To determine whether this was the case in this family (fig IA) , Southern hybridisation was carried out on HindIII digested genomic DNA using the complete IDS cDNA as a probe. All five subjects showed hybridisation patterns identical to the control genomic DNA sample (data not shown). PCR was carried out on genomic DNA from the obligate carrier (IA) with primers spanning each of the nine IDS exons. One primer from each set contained a 5' terminal sequence identical to the M13 universal sequencing primer, while the opposite PCR primer contained a region identical to the Ml 3 reverse sequencing primer. The presence of the IDS pseudogene located distal to the active gene complicated the analysis in the case of exon 3. This exon was first amplified using primers which are specific for IDS exon 3 and do not amplify the nearly identical region of the IDS pseudogene. A second round PCR was then performed using tailed exon 3 primers and purified first round PCR product as template. Amplification was carried out using high fidelity conditions including the use of a proof reading enzyme to minimise the possibility of PCR error. The resulting PCR products were purified by preparative agarose gel eletrophoresis and then sequenced directly using dye primer chemistry and BODIPY universal and reverse dye primers.'6 The resulting sequences were compared to the published genomic sequence, and two mixed bases were observed within exon VIII (fig 1B) . The first base change (T-*A) at nucleotide position 1 150 results in a missense mutation with a histidine amino acid being replaced by a glutamine (H342Q). The second base change (G->T) at nucleotide position 1151 results in a nonsense mutation (G343X).
To confirm that these were true mixed bases this exon was reamplified using primers without universal or reverse tails and then cloned into a vector containing universal and reverse sequencing primer sites. Six individual clones were selected and sequenced in both orientations using dye terminator chemistry. Sequence from three of the six clones was identical to the wild type allele and the other three had sequence identical to the mutant allele identified by direct sequencing of the PCR product (data not shown).
PCR was then performed using DNA from four female members of the family and tailed exon 8 primers. The resulting products were gel purified and sequenced directly using BODIPY dye primer chemistry. Comparison of the resulting sequence to that obtained from the obligate carrier did not detect any mixed bases in any of these subjects, including IIB who had previously been identified as a carrier by skin biopsy (fig 1 B) .
To confirm the results of the sequencing experiments, PCR primers were designed which would specifically amplify either the mutant or the wild type allele (fig 2A) . PCRs performed using either set of wild type specific primers successfully amplified a product of the expected size from all five family members. When the same PCR was performed using primer sets specific for the mutant allele, a product was only obtained using template DNA from the obligate carrier ( fig 2B) .
Discussion
Hunter syndrome shows a wide range of clinical phenotypes. In severely affected subjects the disease is characterised by progressive mental retardation, physical disability, and death occurring before the age of 15.17 The aim of this study was to perform carrier testing in a family affected by severe Hunter syndrome. The obligate carrier (IA) had two children who died of Hunter syndrome at the ages of 3 '/2 and 11 years. Biochemical testing of skin biopsies from one of IA's daughters indicated that she was also a carrier of the disorder. These people are members of a more extensive pedigree consisting of at least nine affected subjects over five generations. Carrier detection in this case was complicated by the fact that no surviving affected subjects were available for study.
Direct dye primer sequencing of PCR products to identify mixed bases has previously been used within our laboratory to analyse the appearance of resistant strains of HIV in patients undergoing AZT treatment (Metzker et The two point mutations identified in the obligate carrier resulted in both a missense and a nonsense mutation. Nonsense mutations have been observed to be associated with either an intermediate or severe phenotype,5 and it is assumed that the truncated proteins produced as a result of these mutations must have little or no enzymatic activity. To our knowledge, this is the first time either of these two mutations has been reported.
Following successful identification of the mutation within the obligate carrier, only the single exon containing the mutation need be amplified and sequenced from other family members. In addition to identifying the mutation in the obligate carrier accurately, we were able to use this approach to show that none of this subject's female descendants had inherited the mutant allele. This included one person who had previously been falsely identified as a carrier by biochemical testing.
An added advantage of this approach is that it will be equally affective when applied to families affected by the mild form of this disorder. In contrast, enzymatic testing requires careful attention to enzyme kinetics and can be unreliable when activity is in the normal range as there is overlap between the ranges of normal and heterozygous subjects. Biochemical testing also often requires analysis of multiple samples from the same person"9 or testing by more than one approach6 20 to give a reliable result.
